VKH
CHRS icon

Virtu KCG Holdings’s Coherus Oncology CHRS Stock Holding History

Virtu KCG Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$602K Buy
+41,947
New +$807K 0.02% 974
2016
Q4 		– Sell
-18,131
Closed -$486K – 3431
2016
Q3 		$486K Buy
+18,131
New +$495K 0.01% 1405

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Virtu KCG Holdings's CHRS Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Coherus Oncology (CHRS) in Q2 2017: 41,947 shares worth $602K. The stake represents 0.02% of the portfolio and ranks #974 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in CHRS as recently as Q3 2016.

Virtu KCG Holdings first reported a position in CHRS in Q3 2016 and has held it in 2 quarters since. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

  • Virtu KCG Holdings held 41,947 shares of Coherus Oncology worth $602K as of Q2 2017.
  • Coherus Oncology was a new Virtu KCG Holdings position in Q2 2017.
  • Coherus Oncology made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #974 holding.
  • Virtu KCG Holdings first reported a position in Coherus Oncology in Q3 2016 and has held it in 2 quarters since.
  • 106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.